Evidence map›Paper›PMID 36145340›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Benzoic Acid Derivatives as Prodrugs for the Treatment of Tuberculosis.

João P Pais, Marta Magalhães, Olha Antoniuk, Ivete Barbosa, Raquel Freire, David Pires, Emília Valente, Bernard Testa, Elsa Anes, Luis Constantino

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Synthesis and structure of benzyl 4-{[4-(hex-yloxy)benzo-yl]-oxy}benzoate.Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
  2. Article
  3. Green Synthesis and Characterization of Silver Nanoparticles UsingInternational journal of microbiology · 2026
    Article
  4. Review
  5. Cystatin F Depletion inInternational journal of molecular sciences · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

João P PaisResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0002-3865-5913
Marta MagalhãesResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Olha AntoniukResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Ivete BarbosaFaculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Raquel FreireResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
David PiresResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0001-9602-1516
Emília ValenteFaculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Bernard TestaUniversity of Lausanne, 1015 Lausanne, Switzerland.
Elsa AnesResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0001-5934-0198
Luis ConstantinoResearch Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0002-6847-4830
University of Lisbon · PTUniversity of Lausanne · CH

Funding

Fundação para a Ciência e Tecnologia Grant EXPL/SAU-INF/1097/2021Fundação para a Ciência e Tecnologia PTDC/SAU-INF/28080/2017Fundação para a Ciência e Tecnologia UIDB/04138/2020Fundação para a Ciência e Tecnologia UIDP/04138/2020
6 · The paper itself

Abstract

One interesting approach to fight tuberculosis is the use of prodrugs that often have shown improved biological activities over drugs with poor absorption or difficulty to cross membranes. Previous studies demonstrate that weak acids such as benzoic acid, present antimycobacterial activity. Moreover, esters of those acids revealed to be a viable alternative since they may diffuse more easily through the cell membranes. Previously we showed that mycobacteria can easily activate benzoic acid esters by conversion to the corresponding acid. Since Zhang postulated that the activity of the acids can be dependent on their pKa, we set up to synthesize a library of benzoates with different electron withdrawing groups (4-chloro, 2,6-dichloro, 3,5-dichloro, 4-nitro, and 3,5 dinitro), to modulate pKa of the liberated acid and different alkoxy substituents (propyl, hexyl, and phenyl) to modulate their lipophilicity, and tested the activity of the esters and the corresponding free acids against mycobacteria. We also studied the activation of the esters by mycobacterial enzymes and the stability of the compounds in buffer and plasma. We concluded that all the benzoates in our study can be activated by mycobacterial enzymes and that the phenyl and hexyl esters presented higher activity than the corresponding free acids, with the nitrobenzoates, and especially the dinitrobenzoates, showing very interesting antitubercular activity that deserve further exploration. Our results did not show a correlation between the activity and the pKa of the acids.

Indexed as

benzoatesesterasesmycobacterianitrobenzoatesprodrugstuberculosis

Identifiers

PMID36145340
PMCPMC9502840
OpenAlexW4295008034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.